(Bloomberg) After fighting off a vocal attack from a short seller less than a year ago, Bavarian Nordic A/S is again the target of hedge funds betting shares in the Danish biotechnology company are set to fall.
Short interest in the developer of cancer vaccines jumped to 11 percent of the share capital this week, according to Markit data. That’s the highest percentage in at least a decade and more than twice the level in August last year, when Kerrisdale Capital Management LLC published reports and hosted conference calls attacking the Danish company’s pipeline.
